You have PCOS and you're gaining weight despite trying everything. Here's why.

Leptin is your body’s master satiety hormone. It’s produced by fat cells and travels to your brain to signal that you’ve eaten enough and can stop eating. This process is the foundation of normal appetite control. When leptin signaling works properly, you naturally feel full after meals and don’t constantly think about food.

LEPR variants, carried by roughly 20-30% of the population, impair this signaling pathway. Your brain doesn’t receive adequate leptin messages, leaving you in a state of perceived starvation even when you’ve eaten enough calories. You feel chronically hungry, obsess over food, and experience intense cravings that standard calorie restriction cannot overcome. This is not a willpower failure; it’s a biological signal mismatch.

For women with PCOS, this becomes even more problematic. Leptin resistance is already part of the PCOS picture, and if you also carry LEPR variants, the effect is compounded. You struggle with constant hunger, weight loss is painfully slow despite strict dieting, and you feel like your body is working against you at every meal.

The FTO gene controls appetite signaling in your hypothalamus, the brain region that decides whether you’re hungry or full. It also influences your food preferences and how much reward you experience from eating. This gene was one of the first to be linked to obesity in large genetic studies, and for good reason: it’s one of the most common genetic influences on appetite control.

The FTO A allele, carried by approximately 45% of people with European ancestry, impairs appetite satiety signaling. You experience reduced fullness cues after eating and are naturally drawn to high-calorie, high-fat foods even when you intellectually know you should eat differently. This isn’t about willpower or self-discipline. Your brain is literally receiving different hunger and reward signals than people without this variant.

In the context of PCOS, this amplifies the metabolic dysregulation. You’re already dealing with hormonal drivers of weight gain, and now add to that a genetic predisposition to eat more and prefer calorie-dense foods. Diets that work fine for others feel impossible for you because your brain is fighting against satiety at every meal.

PPARG is a nuclear receptor that controls how your fat cells behave. It regulates whether your body prefers to store energy as fat or burn it for fuel. It also influences how your cells respond to insulin and inflammatory signals. This is not just about fat accumulation; it’s about metabolic flexibility and how efficiently your body can switch between fed and fasted states.

The PPARG Pro12 allele, carried by roughly 25% of the population, tips the balance toward efficient fat storage. Your fat cells are essentially optimized to accumulate and hold onto energy, making weight loss slower and weight gain easier. Additionally, people with this variant often have a poor metabolic response to low-fat diets. When you restrict fat intake, your body doesn’t adapt well; it simply slows your metabolism and intensifies hunger without shifting stored fat.

For women with PCOS, this is particularly problematic because PCOS already promotes fat storage (especially abdominal fat) through its effects on insulin and androgens. If you also carry PPARG Pro12, your cells are doubly motivated to store fat. Low-fat dieting, the traditional PCOS advice, can actually backfire for you, leaving you hungrier and metabolically suppressed without significant fat loss.

ESR1 encodes the estrogen receptor alpha, the primary cellular receptor through which estrogen exerts its effects throughout your body. This includes effects on fat distribution (visceral vs. subcutaneous), insulin sensitivity, bone density, mood, and inflammation. In women, estrogen normally helps protect against visceral (abdominal) fat accumulation and maintains insulin sensitivity.

ESR1 PvuII and XbaI variants, present in roughly 40% of women, alter estrogen receptor sensitivity. Your cells may not respond optimally to circulating estrogen, even when estrogen levels appear normal on bloodwork. This means you don’t get the normal metabolic protection that estrogen provides. You’re more prone to visceral fat accumulation, impaired insulin sensitivity, and metabolic syndrome, even if standard hormone tests look acceptable.

In PCOS, this becomes critical because the condition already involves abnormal androgen-to-estrogen ratios and impaired estrogen action on fat and metabolic tissue. If you also carry ESR1 variants that reduce estrogen receptor sensitivity, the metabolic dysfunction is compounded. You accumulate more visceral fat, have greater insulin resistance, and experience more mood and cardiovascular risk even with relatively mild PCOS on paper. Standard hormone replacement or lifestyle advice doesn’t account for the fact that your cells may not be responding normally to estrogen itself.

COMT (catechol-O-methyltransferase) clears dopamine, epinephrine, and norepinephrine from your brain and body. These catecholamines are essential for fat mobilization, energy expenditure, mood, and focus. How efficiently you clear these compounds directly impacts your metabolic rate, stress resilience, and how effectively your body can mobilize stored fat during exercise or fasting.

The COMT Val158Met variant, with roughly 25% of people homozygous for slow clearance in European ancestry populations, impairs catecholamine breakdown. You clear dopamine, epinephrine, and norepinephrine more slowly, leading to chronic adrenal activation, burnout, and a metabolic state biased toward fat storage over fat mobilization. Your nervous system stays in a semi-activated state, which paradoxically suppresses weight loss by keeping cortisol elevated and making it harder to mobilize stored fat.

In PCOS, slow COMT becomes particularly problematic because the condition already involves chronic low-grade inflammation and HPA axis dysregulation. You’re more easily stressed, slower to recover from stress, and more likely to be stuck in a fight-or-flight state that prevents fat mobilization. Exercise feels harder. Recovery is slower. Your metabolism stays suppressed. And the elevated stress hormones themselves worsen androgen excess and insulin resistance, the core PCOS drivers.

MTHFR (methylenetetrahydrofolate reductase) catalyzes a critical step in the methylation cycle, the biochemical pathway that produces methylated compounds needed for energy production, hormone metabolism, DNA synthesis, and detoxification. Every cell in your body depends on methylation to function properly. This is especially true in metabolic tissues like liver and muscle, and in reproductive tissues affected by hormonal changes.

The MTHFR C677T variant, carried by approximately 40% of people with European ancestry, reduces enzyme efficiency by 40-70%. Your methylation cycle is suppressed, meaning your cells produce less energy, process hormones less efficiently, and clear metabolic waste products more slowly. You can eat a perfect diet and still experience fatigue, brain fog, and suppressed fat metabolism because the cellular machinery for energy production is running at partial capacity.

For women with PCOS, this has direct consequences. Impaired methylation worsens homocysteine metabolism, which impairs insulin sensitivity. It also reduces your ability to process and clear excess androgens, worsening hormonal imbalance. Your fat cells have difficulty mobilizing stored fat because they’re energy-depleted. And your liver, responsible for detoxifying hormones, works less efficiently, allowing excess estrogen and androgens to circulate longer and accumulate in fat tissue. The net effect is metabolic suppression compounded by hormonal recycling.